Status:
COMPLETED
Safety/Tolerability, Pharmacokinetics/Pharmacodynamics (PK/PD) of LCZ696 in Patients With Stable Heart Failure
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Heart Failure
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study assess the safety/tolerability, PK/PD of LCZ696 in patients with stable heart failure.
Eligibility Criteria
Inclusion
- Patients with documented heart failure (NYHA class II-IV)
Exclusion
- Use of both ACEi and ARB, ACEi and DRI, ARB and DRI treatment, or all three medications at Screening
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00913653
Start Date
May 1 2009
Last Update
December 19 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GOUVPO Russian Peoples´ Friendship University, Center of Applied
Moscow, Russia, 117198